Agile Therapeutics Inc (STU:0AL)
€ 9.83 0 (0%) Market Cap: 7.41 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 19/100

Agile Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 12:30PM GMT
Release Date Price: €666.4 (-0.18%)
Sushil Bhandaru

Good morning, and welcome to the 40th Annual JPMorgan Healthcare Conference. My name is Sushil Bhandaru, and I'm an analyst in JPMorgan's health care group.

Before we begin today's session, we want to call attention to the blue question box at the bottom of your screen. (Operator Instructions)

With that, I'm pleased to introduce Al Altomari, Chairman and CEO of Agile Therapeutics, to tell you a bit more about their business.

Alfred F. Altomari
Agile Therapeutics, Inc. - Chairman & CEO

Thanks, Sushil. So first of all, thank you for the introduction, and I'd also like to take a moment to thank JPMorgan, particularly Mike Gaito and the banking team, for giving us this opportunity to provide an update in what a really important time for Agile Therapeutics.

So just to remind everybody, Agile Therapeutics is a publicly traded company. And throughout my presentation, I will be making forward-looking statements. So I'd encourage you to take a look at all our most recent filings that are available either on our corporate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot